Allison Inserro

April 15, 2019

The 2-part proposal from Peter B. Bach, MD, and 3 coauthors published Monday argues that biosimilar competition is an economically inefficient way to achieve the goal of lower prices.

April 13, 2019

During the last panel at the Alliance for Patient Access 4th Annual National Policy and Advocacy Summit on Biologics and Biosimilars, panelists discussed some of the administration’s proposals, such as moving Medicare Part B drugs to Part D, a proposal to end protected drug classes in Medicare, and the International Price Index.

April 12, 2019

Two leaders of the Alliance for Patient Access discussed results of a survey and focus group about nonmedical switching of patients from one drug to another by payers and pharmacy benefit managers for reasons of cost.

April 11, 2019

The theme of the Alliance for Patient Access 4th Annual National Policy and Advocacy Summit on Biologics and Biosimilars meeting was all about value, and panelists from the Aimed Alliance and the Partnership to Advance Cardiovascular Health discussed how they used the concept of value in their discussions with payers.

April 10, 2019

At the 4th Annual Policy and Advocacy Summit on Biologics and Biosimilars of the Alliance for Patient Access, speakers discussed the fact that while numerous biosimilars have been approved, most have not reached the market in the United States.

April 10, 2019

Before the Senate Finance Committee, pharmacy benefit managers said legal issues, not their actions, were to blame for keeping biosimilars from reaching US patients.

April 08, 2019

An advocacy group for patients with breast cancer in Canada recently published a series of recommendations after convening roundtable discussions with both patients and providers about their knowledge of biosimilars.

April 05, 2019

Biosana Pty Ltd, a subsidiary of BiosanaPharma BV, says it received permission from the Australian Bellberry Human Research Ethics Committee (HREC) to start a phase 1 trial for a biosimilar version of omalizumab.

April 04, 2019

In December 2018, the FDA announced its guidance for industry on the interpretation of the “Deemed to be a License” provision in section 7002(e) of the Biologics Price Competition and Innovation Act. The bill introduced this week would codify those guidelines, as they pertain to insulin, into law to prevent any future administrations from revoking them.

April 03, 2019

As legislators consider policy and regulatory options to lower the cost of prescription drugs, the American College of Rheumatology (ACR) is calling for an end to step therapy (or sometimes called “fail first” policies) as well as the switching of medications in stable patients purely for cost reasons.